EC Number | Crystallization (Comment) | Organism |
---|---|---|
2.4.2.8 | purified enzyme in complex with inhibitor [3-(guanine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methylphosphonic acid and ([3-(guanine-9-yl)-2-((2-phosphonoethoxy)-methyl)propoxy]methyl)phosphonic acid, hanging drop method, mixing of 0.001 ml of 11.1 mg/ml protein in 0.1 M Tris-HCl, 0.01 M MgCl2, 1 mM DTT, and 0.3 mM 5-phospho-alpha-D-ribose 1-diphosphate, pH 7.4, and 4.8 mM inhibitor, with 0.001 ml of reservoir solution containing 20% PEG 3350, 0.2 M sodium bromide, 0.1 M Bis-Tris propane, pH 7.5, at 18°C, X-ray diffraction structure determination and analysis at 2.0 A resolution, molecular replacement and modeling | Homo sapiens |
EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
2.4.2.8 | (2-[3-(8-bromoguanin-9-yl)-2-(2-(bishydroxyphosphoryl)-ethoxy)propoxy]ethyl)phosphonic acid | - |
Homo sapiens | |
2.4.2.8 | (2-[3-(8-bromoguanin-9-yl)-2-(2-(bishydroxyphosphoryl)-ethoxy)propoxy]ethyl)phosphonic acid | - |
Plasmodium falciparum | |
2.4.2.8 | ([2-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-3-(2-phosphonoethoxy)propoxy]methyl)phosphonic acid | - |
Homo sapiens | |
2.4.2.8 | ([2-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-3-(2-phosphonoethoxy)propoxy]methyl)phosphonic acid | - |
Plasmodium falciparum | |
2.4.2.8 | ([2-[(6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-3-(2-phosphonoethoxy)propoxy]methyl)phosphonic acid | - |
Homo sapiens | |
2.4.2.8 | ([2-[(6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-3-(2-phosphonoethoxy)propoxy]methyl)phosphonic acid | - |
Plasmodium falciparum | |
2.4.2.8 | ([3-(7-deazaguanine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methyl)phosphonic acid | sodium salt | Homo sapiens | |
2.4.2.8 | ([3-(7-deazaguanine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methyl)phosphonic acid | sodium salt | Plasmodium falciparum | |
2.4.2.8 | ([3-(7-deazahypoxanthine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methyl)phosphonic acid | sodium salt | Homo sapiens | |
2.4.2.8 | ([3-(7-deazahypoxanthine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methyl)phosphonic acid | sodium salt | Plasmodium falciparum | |
2.4.2.8 | ([3-(8-bromoguanine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methyl)phosphonic acid | sodium salt | Homo sapiens | |
2.4.2.8 | ([3-(8-bromoguanine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methyl)phosphonic acid | sodium salt | Plasmodium falciparum | |
2.4.2.8 | ([3-(8-bromohypoxanthine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methyl)phosphonic acid | sodium salt | Homo sapiens | |
2.4.2.8 | ([3-(8-bromohypoxanthine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methyl)phosphonic acid | sodium salt | Plasmodium falciparum | |
2.4.2.8 | ([3-(guanine-9-yl)-2-((2-phosphonoethoxy)-methyl)propoxy]methyl)phosphonic acid | sodium salt | Homo sapiens | |
2.4.2.8 | ([3-(guanine-9-yl)-2-((2-phosphonoethoxy)-methyl)propoxy]methyl)phosphonic acid | sodium salt | Plasmodium falciparum | |
2.4.2.8 | ([3-(hypoxanthine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methyl)phosphonic acid | sodium salt | Homo sapiens | |
2.4.2.8 | ([3-(hypoxanthine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methyl)phosphonic acid | sodium salt | Plasmodium falciparum | |
2.4.2.8 | diethyl (2S,15S)-2,15-dibenzyl-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-8-[(4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl]-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate | prodrug | Homo sapiens | |
2.4.2.8 | diethyl (2S,15S)-2,15-dibenzyl-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-8-[(4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl]-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate | prodrug | Plasmodium falciparum | |
2.4.2.8 | diethyl (2S,15S)-2,15-dibenzyl-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-8-[(6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate | prodrug | Homo sapiens | |
2.4.2.8 | diethyl (2S,15S)-2,15-dibenzyl-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-8-[(6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate | prodrug | Plasmodium falciparum | |
2.4.2.8 | diethyl (2S,15S)-2,15-dibenzyl-8-[(8-bromo-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate | prodrug | Homo sapiens | |
2.4.2.8 | diethyl (2S,15S)-2,15-dibenzyl-8-[(8-bromo-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate | prodrug | Plasmodium falciparum | |
2.4.2.8 | diethyl (2S,15S)-4,13-bis[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-4,13-dioxo-8-[(6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-2,15-bis(2-phenylethyl)-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate | - |
Homo sapiens | |
2.4.2.8 | diethyl (2S,15S)-4,13-bis[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-4,13-dioxo-8-[(6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-2,15-bis(2-phenylethyl)-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate | - |
Plasmodium falciparum | |
2.4.2.8 | diethyl (2S,15S)-8-[(2-amino-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl]-2,15-dibenzyl-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate | prodrug | Homo sapiens | |
2.4.2.8 | diethyl (2S,15S)-8-[(2-amino-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl]-2,15-dibenzyl-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate | prodrug | Plasmodium falciparum | |
2.4.2.8 | diethyl (2S,15S)-8-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-2,15-dibenzyl-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate | prodrug | Homo sapiens | |
2.4.2.8 | diethyl (2S,15S)-8-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-2,15-dibenzyl-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate | prodrug | Plasmodium falciparum | |
2.4.2.8 | diethyl (2S,15S)-8-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-2,15-dibenzyl-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-7,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate | prodrug | Homo sapiens | |
2.4.2.8 | diethyl (2S,15S)-8-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-2,15-dibenzyl-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-7,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate | prodrug | Plasmodium falciparum | |
2.4.2.8 | diethyl (2S,15S)-8-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-4,13-bis[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-4,13-dioxo-2,15-bis(2-phenylethyl)-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate | - |
Homo sapiens | |
2.4.2.8 | diethyl (2S,15S)-8-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-4,13-bis[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-4,13-dioxo-2,15-bis(2-phenylethyl)-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate | - |
Plasmodium falciparum | |
2.4.2.8 | diethyl (2S,15S)-8-[(2-amino-8-bromo-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-2,15-dibenzyl-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-7,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate | prodrug | Homo sapiens | |
2.4.2.8 | diethyl (2S,15S)-8-[(2-amino-8-bromo-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-2,15-dibenzyl-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-7,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate | prodrug | Plasmodium falciparum | |
2.4.2.8 | additional information | synthesis and evaluation of asymmetric acyclic nucleoside bisphosphonates as inhibitors of human hypoxanthine-guanine phosphoribosyltransferase | Homo sapiens | |
2.4.2.8 | additional information | synthesis and evaluation of asymmetric acyclic nucleoside bisphosphonates as inhibitors of Plasmodium falciparum hypoxanthine-guanine-(xanthine) phosphoribosyltransferase. Low Ki values are achieved by inserting an extra carbon atom in the linker connecting the N9 atom of guanine to one of the phosphonate groups | Plasmodium falciparum | |
2.4.2.8 | [3-(guanine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methylphosphonic acid | structure bound in the active site of human HGPRT (PDB ID 4IJQ), molecular docking. The crystal structure shows that a magnesium ion is coordinated to one of the sulfate oxygen atoms and one of the phosphonate oxygen atoms of the inhibitor | Homo sapiens | |
2.4.2.8 | [3-(guanine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methylphosphonic acid | - |
Plasmodium falciparum | |
2.4.2.8 | [[2-[(6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]propane-1,3-diyl]bis(oxymethylene)]bis(phosphonic acid) | - |
Homo sapiens | |
2.4.2.8 | [[2-[(6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]propane-1,3-diyl]bis(oxymethylene)]bis(phosphonic acid) | - |
Plasmodium falciparum | |
2.4.2.22 | (2-[3-(8-bromoguanin-9-yl)-2-(2-(bishydroxyphosphoryl)-ethoxy)propoxy]ethyl)phosphonic acid | - |
Plasmodium falciparum | |
2.4.2.22 | ([2-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-3-(2-phosphonoethoxy)propoxy]methyl)phosphonic acid | - |
Plasmodium falciparum | |
2.4.2.22 | ([2-[(6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-3-(2-phosphonoethoxy)propoxy]methyl)phosphonic acid | - |
Plasmodium falciparum | |
2.4.2.22 | ([3-(7-deazaguanine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methyl)phosphonic acid | sodium salt | Plasmodium falciparum | |
2.4.2.22 | ([3-(7-deazahypoxanthine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methyl)phosphonic acid | sodium salt | Plasmodium falciparum | |
2.4.2.22 | ([3-(8-bromoguanine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methyl)phosphonic acid | sodium salt | Plasmodium falciparum | |
2.4.2.22 | ([3-(8-bromohypoxanthine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methyl)phosphonic acid | sodium salt | Plasmodium falciparum | |
2.4.2.22 | ([3-(guanine-9-yl)-2-((2-phosphonoethoxy)-methyl)propoxy]methyl)phosphonic acid | sodium salt | Plasmodium falciparum | |
2.4.2.22 | ([3-(hypoxanthine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methyl)phosphonic acid | sodium salt | Plasmodium falciparum | |
2.4.2.22 | diethyl (2S,15S)-2,15-dibenzyl-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-8-[(4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl]-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate | prodrug | Plasmodium falciparum | |
2.4.2.22 | diethyl (2S,15S)-2,15-dibenzyl-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-8-[(6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate | prodrug | Plasmodium falciparum | |
2.4.2.22 | diethyl (2S,15S)-2,15-dibenzyl-8-[(8-bromo-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate | prodrug | Plasmodium falciparum | |
2.4.2.22 | diethyl (2S,15S)-4,13-bis[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-4,13-dioxo-8-[(6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-2,15-bis(2-phenylethyl)-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate | - |
Plasmodium falciparum | |
2.4.2.22 | diethyl (2S,15S)-8-[(2-amino-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl]-2,15-dibenzyl-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate | prodrug | Plasmodium falciparum | |
2.4.2.22 | diethyl (2S,15S)-8-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-2,15-dibenzyl-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate | prodrug | Plasmodium falciparum | |
2.4.2.22 | diethyl (2S,15S)-8-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-2,15-dibenzyl-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-7,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate | prodrug | Plasmodium falciparum | |
2.4.2.22 | diethyl (2S,15S)-8-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-4,13-bis[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-4,13-dioxo-2,15-bis(2-phenylethyl)-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate | - |
Plasmodium falciparum | |
2.4.2.22 | diethyl (2S,15S)-8-[(2-amino-8-bromo-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-2,15-dibenzyl-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-7,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate | prodrug | Plasmodium falciparum | |
2.4.2.22 | additional information | synthesis and evaluation of asymmetric acyclic nucleoside bisphosphonates as inhibitors of Plasmodium falciparum hypoxanthine-guanine-(xanthine) phosphoribosyltransferase. Low Ki values are achieved by inserting an extra carbon atom in the linker connecting the N9 atom of guanine to one of the phosphonate groups | Plasmodium falciparum | |
2.4.2.22 | [3-(guanine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methylphosphonic acid | - |
Plasmodium falciparum | |
2.4.2.22 | [[2-[(6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]propane-1,3-diyl]bis(oxymethylene)]bis(phosphonic acid) | - |
Plasmodium falciparum |
EC Number | Metals/Ions | Comment | Organism | Structure |
---|---|---|---|---|
2.4.2.8 | Mg2+ | required | Homo sapiens | |
2.4.2.8 | Mg2+ | required | Plasmodium falciparum | |
2.4.2.22 | Mg2+ | required | Plasmodium falciparum |
EC Number | Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
2.4.2.8 | guanosine + 5-phospho-alpha-D-ribose 1-diphosphate | Homo sapiens | - |
GMP + diphosphate | - |
? | |
2.4.2.8 | guanosine + 5-phospho-alpha-D-ribose 1-diphosphate | Plasmodium falciparum | - |
GMP + diphosphate | - |
? | |
2.4.2.8 | hypoxanthine + 5-phospho-alpha-D-ribose 1-diphosphate | Homo sapiens | - |
IMP + diphosphate | - |
? | |
2.4.2.8 | hypoxanthine + 5-phospho-alpha-D-ribose 1-diphosphate | Plasmodium falciparum | - |
IMP + diphosphate | - |
? | |
2.4.2.8 | xanthine + 5-phospho-alpha-D-ribose 1-diphosphate | Plasmodium falciparum | reaction of EC 2.4.2.22 | XMP + diphosphate | - |
? | |
2.4.2.22 | guanosine + 5-phospho-alpha-D-ribose 1-diphosphate | Plasmodium falciparum | - |
GMP + diphosphate | - |
? | |
2.4.2.22 | hypoxanthine + 5-phospho-alpha-D-ribose 1-diphosphate | Plasmodium falciparum | reaction of EC 2.4.2.8 | IMP + diphosphate | - |
? | |
2.4.2.22 | xanthine + 5-phospho-alpha-D-ribose 1-diphosphate | Plasmodium falciparum | - |
XMP + diphosphate | - |
? |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
2.4.2.8 | Homo sapiens | P00492 | - |
- |
2.4.2.8 | Plasmodium falciparum | Q8IJS1 | - |
- |
2.4.2.22 | Plasmodium falciparum | Q8IJS1 | - |
- |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
2.4.2.8 | A-549 cell | - |
Homo sapiens | - |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
2.4.2.8 | guanosine + 5-phospho-alpha-D-ribose 1-diphosphate | - |
Homo sapiens | GMP + diphosphate | - |
? | |
2.4.2.8 | guanosine + 5-phospho-alpha-D-ribose 1-diphosphate | - |
Plasmodium falciparum | GMP + diphosphate | - |
? | |
2.4.2.8 | hypoxanthine + 5-phospho-alpha-D-ribose 1-diphosphate | - |
Homo sapiens | IMP + diphosphate | - |
? | |
2.4.2.8 | hypoxanthine + 5-phospho-alpha-D-ribose 1-diphosphate | - |
Plasmodium falciparum | IMP + diphosphate | - |
? | |
2.4.2.8 | xanthine + 5-phospho-alpha-D-ribose 1-diphosphate | reaction of EC 2.4.2.22 | Plasmodium falciparum | XMP + diphosphate | - |
? | |
2.4.2.22 | guanosine + 5-phospho-alpha-D-ribose 1-diphosphate | - |
Plasmodium falciparum | GMP + diphosphate | - |
? | |
2.4.2.22 | hypoxanthine + 5-phospho-alpha-D-ribose 1-diphosphate | reaction of EC 2.4.2.8 | Plasmodium falciparum | IMP + diphosphate | - |
? | |
2.4.2.22 | xanthine + 5-phospho-alpha-D-ribose 1-diphosphate | - |
Plasmodium falciparum | XMP + diphosphate | - |
? |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
2.4.2.8 | HGPRT | - |
Homo sapiens |
2.4.2.8 | hypoxanthine-guanine phosphoribosyltransferase | - |
Homo sapiens |
2.4.2.8 | hypoxanthine-guanine-(xanthine) phosphoribosyltransferase | - |
Plasmodium falciparum |
2.4.2.8 | More | see also EC 2.4.2.22 | Plasmodium falciparum |
2.4.2.8 | Pf HGXPRT | - |
Plasmodium falciparum |
2.4.2.22 | hypoxanthine-guanine-(xanthine) phosphoribosyltransferase | - |
Plasmodium falciparum |
2.4.2.22 | More | see also EC 2.4.2.8 | Plasmodium falciparum |
2.4.2.22 | Pf HGXPRT | - |
Plasmodium falciparum |
EC Number | pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
---|---|---|---|---|
2.4.2.8 | 7.4 | - |
assay at | Homo sapiens |
2.4.2.8 | 7.4 | - |
assay at | Plasmodium falciparum |
2.4.2.22 | 7.4 | - |
assay at | Plasmodium falciparum |
EC Number | Ki Value [mM] | Ki Value maximum [mM] | Inhibitor | Comment | Organism | Structure |
---|---|---|---|---|---|---|
2.4.2.8 | 0.000006 | - |
[3-(guanine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methylphosphonic acid | pH 7.4, temperature not specified in the publication | Plasmodium falciparum | |
2.4.2.8 | 0.00007 | - |
[3-(guanine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methylphosphonic acid | pH 7.4, temperature not specified in the publication | Homo sapiens | |
2.4.2.22 | 0.000006 | - |
[3-(guanine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methylphosphonic acid | pH 7.4, temperature not specified in the publication | Plasmodium falciparum |
EC Number | General Information | Comment | Organism |
---|---|---|---|
2.4.2.8 | physiological function | hypoxanthine-guanine-(xanthine) phosphoribosyltransferases, HG(X)PRTs, catalyze the formation of the 6-oxopurine nucleoside monophosphates from a nucleobase and from 5'-phospho-alpha-D-ribosyl-1-diphosphate | Plasmodium falciparum |
2.4.2.8 | physiological function | hypoxanthine-guanine-(xanthine) phosphoribosyltransferases, HG(X)PRTs, catalyze the formation of the 6-oxopurine nucleoside monophosphates from a nucleobase and from 5'-phospho-alpha-D-ribosyl-1-pyrophosphate | Homo sapiens |
2.4.2.22 | physiological function | hypoxanthine-guanine-(xanthine) phosphoribosyltransferases, HG(X)PRTs, catalyze the formation of the 6-oxopurine nucleoside monophosphates from a nucleobase and from 5'-phospho-alpha-D-ribosyl-1-pyrophosphate | Plasmodium falciparum |